Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

Fast and accurate short read alignment with Burrows-Wheeler transform

Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895

A framework for variation discovery and genotyping using next-generation DNA sequencing data

DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,457

dbSNP: the NCBI database of genetic variation

Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509

Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor

Söker, S., Takashima, S., Miao, H. Q., Neufeld, G., & Klagsbrun, M. (1998) · Cell · doi:10.1016/s0092-8674(00)81402-6 · Cited by 2,493

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,417

Chimeric Antigen Receptor Therapy

June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,411

Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy

Zhang, Z., Chen, X., Tian, Y., Li, F., Zhao, X., Liu, J., Yao, C., & Zhang, Y. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001150 · Cited by 88

Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment

Watanabe, N., McKenna, M. K., Shaw, A. R., & Suzuki, M. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.023 · Cited by 84

Allogeneic CAR T cell therapies for leukemia

Qasim, W. (2019) · American Journal of Hematology · doi:10.1002/ajh.25399 · Cited by 86

Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation

Andorko, J. I., Russell, R. M., Schnepp, B. C., Grubaugh, D., Mullen, K. F., Wakabayashi, A., Carrington, L. J., O’Malley, T. M., Kuri-Cervantes, L., Culp, T. D., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.036 · Cited by 90

Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies

Li, Y.-R., Halladay, T., & Yang, L. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-00998-8 · Cited by 85

Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors.

Frank, A. M., Braun, A. H., Scheib, L., Agarwal, S., Schneider, I. C., Fusil, F., Perian, S., Sahin, U., Thalheimer, F. B., Verhoeyen, E., et al. (2020) · PubMed Central · doi:10.1182/bloodadvances.2020002229 · Cited by 78

Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications

Blache, U., Weiss, R., Boldt, A., Kapinsky, M., Blaudszun, A., Quaiser, A., Pohl, A., Miloud, T., Burgaud, M., Vučinić, V., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658314 · Cited by 81

Fratricide-resistant CD7-CAR T cells in T-ALL

Oh, B. L. Z., Shimasaki, N., Coustan‐Smith, E., Chan, E., Poon, L. M., Lee, S. H. R., Yeap, F., Tan, L. K., Chai, L. Y. A., Bert, N. L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03228-8 · Cited by 79

Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL

Korell, F., Laier, S., Sauer, S., Veelken, K., Hennemann, H., Schubert, M., Sauer, T., Pavel, P., Müller‐Tidow, C., Dreger, P., et al. (2020) · Cells · doi:10.3390/cells9051225 · Cited by 76

Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells

Hiltensperger, M., & Krackhardt, A. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1121030 · Cited by 79

Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies

Mhaidly, R., & Verhoeyen, E. (2020) · Cancers · doi:10.3390/cancers12071915 · Cited by 76

Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review

Aparicio, C., Acebal, C., & González‐Vallinas, M. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00435-w · Cited by 82

Chimeric Antigen Receptors for T-Cell Malignancies

Scherer, L. D., Brenner, M. K., & Mamonkin, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00126 · Cited by 73

Accelerating and optimising CAR T-cell manufacture to deliver better patient products

Agliardi, G., Dias, J., Rampotas, A., Garcia, J., & Roddie, C. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00273-4 · Cited by 79

Improving CAR T cell therapy by optimizing critical quality attributes

Reddy, O. L., Stroncek, D. F., & Panch, S. R. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.07.005 · Cited by 74

CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?

Kozani, P. S., Kozani, P. S., & Rahbarizadeh, F. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02595-0 · Cited by 76

Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies

Guercio, M., Manni, S., Boffa, I., Caruso, S., Cecca, S. D., Sinibaldi, M., Abbaszadeh, Z., Camera, A., Ciccone, R., Polito, V. A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.755639 · Cited by 72

Genome editing of donor-derived T-cells to generate allogenic chimeric antigen receptor-modified T cells: Optimizing αβ T cell-depleted haploidentical hematopoietic stem cell transplantation

Wiebking, V., Lee, C. M., Mostrel, N., Lahiri, P., Bak, R. O., Bao, G., Roncarolo, M. G., Bertaina, A., & Porteus, M. H. (2020) · Haematologica · doi:10.3324/haematol.2019.233882 · Cited by 73

CAR T cells: Building on the CD19 paradigm

Levin, A. G., Rivière, I., Eshhar, Z., & Sadelain, M. (2021) · European Journal of Immunology · doi:10.1002/eji.202049064 · Cited by 68

Genome-edited allogeneic donor “universal” chimeric antigen receptor T cells

Qasim, W. (2022) · Blood · doi:10.1182/blood.2022016204 · Cited by 70

Quantitative Control of Gene-Engineered T-Cell Activity through the Covalent Attachment of Targeting Ligands to a Universal Immune Receptor

Minutolo, N. G., Sharma, P., Poussin, M., Shaw, L. C., Brown, D. P., Hollander, E. E., Smole, A., Rodríguez-García, A., Hui, J. Z., Zappala, F., et al. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b11622 · Cited by 73

CD38 as a pan-hematologic target for chimeric antigen receptor T cells

Glisovic‐Aplenc, T., Diorio, C. J., Chukinas, J. A., Veliz, K., Shestova, O. E., Shen, F., Nuñez-Cruz, S., Vincent, T. L., Miao, F., Milone, M. C., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022007059 · Cited by 70

The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice

Cerrano, M., Ruella, M., Perales, M., Vitale, C., Faraci, D., Giaccone, L., Coscia, M., Maloy, M., Sánchez‐Escamilla, M., Elsabah, H., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00888 · Cited by 71

Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape

Zhai, Y., Du, Y., Li, G., Yu, M., Hu, H., Pan, C., Wang, D., Shi, Z., Yan, X., Li, X., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01708-w · Cited by 74

Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer

Gorchakov, A. A., Kulemzin, S. V., Kochneva, G. V., & Taranin, A. V. (2019) · European Urology · doi:10.1016/j.eururo.2019.08.014 · Cited by 66

Tumor buster - where will the CAR-T cell therapy ‘missile’ go?

Qu, C., Zhang, H., Cao, H., Tang, L., Mo, H., Liu, F., Zhang, L., Yi, Z., Long, L., Yan, L., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01669-8 · Cited by 68

Chimeric Antigen Receptor beyond CAR-T Cells

Qin, V. M., D’Souza, C., Neeson, P. J., & Zhu, J. J. (2021) · Cancers · doi:10.3390/cancers13030404 · Cited by 65

Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies

Yan, X., Chen, D., Wang, Y., Guo, Y., Tong, C., Wei, J., Zhang, Y., Wu, Z., & Han, W. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00915-1 · Cited by 65

Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression

Mueller, K. P., Piscopo, N. J., Forsberg, M. H., Saraspe, L. A., Das, A., Russell, B., Smerchansky, M. E., Cappabianca, D., Shi, L., Shankar, K., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004446 · Cited by 62

Immune-Based Therapies in Acute Leukemia

Witkowski, M. T., Lasry, A., Carroll, W. L., & Aifantis, I. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.07.009 · Cited by 65

Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL

Pérez, C. A., Carmona-Luque, M. D., Benabdellah, K., & Herrera, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1165870 · Cited by 69

Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing

Noaks, E., Peticone, C., Kotsopoulou, E., & Bracewell, D. G. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.002 · Cited by 62

Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma

Köksal, H., Dillard, P., Josefsson, S. E., Maggadottir, S. M., Pollmann, S., Fåne, A., Blaker, Y. N., Beiske, K., Huse, K., Kolstad, A., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018029678 · Cited by 67

Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities

Bashash, D., Zandi, Z., Kashani, B., Pourbagheri‐Sigaroodi, A., Salari, S., & Ghaffari, S. H. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30575 · Cited by 62

CD19 Chimeric Antigen Receptor-Exosome Targets CD19 Positive B-lineage Acute Lymphocytic Leukemia and Induces Cytotoxicity

Haque, S., & Vaiselbuh, S. R. (2021) · Cancers · doi:10.3390/cancers13061401 · Cited by 59

Discovery of a Transferrin Receptor 1-Binding Aptamer and Its Application in Cancer Cell Depletion for Adoptive T-Cell Therapy Manufacturing

Cheng, E. L., Cardle, I. I., Kacherovsky, N. A., Bansia, H., Wang, T., Zhou, Y., Raman, J., Yen, A., Gutierrez, D., Salipante, S. J., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c05349 · Cited by 60

CAR-T cell-derived exosomes: a new perspective for cancer therapy

Sani, F., Shojaei, S., Tabatabaei, S. A., Khorraminejad‐Shirazi, M., Latifi, M., Sani, M., & Azarpira, N. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03783-4 · Cited by 66

Engineering strategies to safely drive CAR T-cells into the future

Rossi, M., & Breman, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1411393 · Cited by 68

Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies

Song, M.-K., Park, B.-B., & Uhm, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205010 · Cited by 62

Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies

Zheng, S., Gillespie, E., Naqvi, A. S., Hayer, K. E., Ang, Z., Torres-Diz, M., Quesnel-Vallières, M., Hottman, D. A., Bagashev, A., Chukinas, J., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0087 · Cited by 59

Late Effects after Chimeric Antigen Receptor T Cell Therapy for Lymphoid Malignancies

Chakraborty, R., Hill, B. T., Majeed, A., & Majhail, N. S. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2020.10.002 · Cited by 58

Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments

Xu, X., Huang, S., Xiao, X., Sun, Q., Liang, X., Chen, S., Zhao, Z., Huo, Z., Tu, S., & Li, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.569117 · Cited by 62

The role of MSCs and CAR-MSCs in cellular immunotherapy

Yan, L., Li, J., & Zhang, C. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01191-4 · Cited by 59

Complications after CD19+ CAR T-Cell Therapy

Penack, O., & Koenecke, C. (2020) · Cancers · doi:10.3390/cancers12113445 · Cited by 59

Hematopoietic Stem Cell- and Induced Pluripotent Stem Cell-Derived CAR-NK Cells as Reliable Cell-Based Therapy Solutions

Arias, J., Yu, J., Varshney, M., Inzunza, J., & Nalvarte, I. (2021) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0459 · Cited by 56

Novel Redirected T–Cell Immunotherapies for Advanced Prostate Cancer

Dorff, T. B., Narayan, V., Forman, S. J., Zang, P. D., Fraietta, J. A., June, C. H., Haas, N. B., & Priceman, S. J. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1483 · Cited by 59

Novel Immunotherapies for Osteosarcoma

Lu, Y., Zhang, J., Chen, Y., Kang, Y., Liao, Z., He, Y., & Zhang, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.830546 · Cited by 58

The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine

Li, X., Li, M., Huang, M., Lin, Q., Fang, Q., Liu, J., Chen, X., Liu, L., Zhan, X., Shan, H., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113064 · Cited by 57

Strategies for Dodging the Obstacles in CAR T Cell Therapy

Kozani, P. S., Kozani, P. S., Rahbarizadeh, F., & Nikkhoi, S. K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.627549 · Cited by 57

CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More

Ou, X., Ma, Q., Yin, W., Ma, X., & He, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.674467 · Cited by 58

Assessing Tumorigenicity in Stem Cell-Derived Therapeutic Products: A Critical Step in Safeguarding Regenerative Medicine

Wang, Z. (2023) · Bioengineering · doi:10.3390/bioengineering10070857 · Cited by 58

High-Throughput In Vivo Screening Identifies Differential Influences on mRNA Lipid Nanoparticle Immune Cell Delivery by Administration Route

Hamilton, A. G., Swingle, K. L., Thatte, A. S., Mukalel, A. J., Safford, H. C., Billingsley, M. M., El-Mayta, R. D., Han, X., Nachod, B. E., Joseph, R. A., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c01171 · Cited by 65

Abrogation of HLA surface expression using CRISPR/Cas9 genome editing: a step toward universal T cell therapy

Lee, J., Sheen, J. H., Lim, O., Lee, Y. J., Ryu, J., Shin, D., Kim, Y. Y., & Kim, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-74772-9 · Cited by 54

Recent updates on allogeneic CAR-T cells in hematological malignancies

Mansoori, S., Noei, A., Maali, A., Seyed-Motahari, S. S., & Sharifzadeh, Z. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03479-y · Cited by 57

Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy

Lu, Y., & Fu, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02334-6 · Cited by 58

T Lymphocyte and CAR-T Cell-Derived Extracellular Vesicles and Their Applications in Cancer Therapy

Calvo, V., & Izquierdo, M. (2022) · Cells · doi:10.3390/cells11050790 · Cited by 56

BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice

Zhou, X., Rasche, L., Kortüm, K. M., Mersi, J., & Einsele, H. (2022) · Haematologica · doi:10.3324/haematol.2020.266841 · Cited by 59

The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches

Weiner, D. M., Durgin, J. S., Wysocka, M., & Rook, A. H. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.12.026 · Cited by 53

Automated generation of gene-edited CAR T cells at clinical scale

Alzubi, J., Lock, D., Rhiel, M., Schmitz, S., Wild, S., Mussolino, C., Hildenbeutel, M., Brandes, C., Rositzka, J., Lennartz, S., et al. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.12.008 · Cited by 53

All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy

Lanitis, E., Coukos, G., & Irving, M. B. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.01.009 · Cited by 52

Incorporation of clove essential oil nanoemulsion in chitosan coating to control Burkholderia gladioli and improve postharvest quality of fresh Tremella fuciformis

Wang, H., Ma, Y., Liu, L., Liu, Y., & Niu, X. (2022) · LWT · doi:10.1016/j.lwt.2022.114059 · Cited by 51

Integration of ζ-deficient CARs into the CD3 ζ gene conveys potent cytotoxicity in T and NK cells

Kath, J., Franke, C., Drosdek, V., Du, W., Glaser, V., Fuster‐García, C., Stein, M., Zittel, T., Schulenberg, S., Porter, C. E., et al. (2024) · Blood · doi:10.1182/blood.2023020973 · Cited by 52

CD5 deletion enhances the antitumor activity of adoptive T cell therapies

Patel, R. P., Ghilardi, G., Zhang, Y., Chiang, Y., Xie, W., Guruprasad, P., Kim, K. H., Chun, I., Angelos, M. G., Pajarillo, R., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adn6509 · Cited by 55

Progress and challenges in developing allogeneic cell therapies

Deuse, T., & Schrepfer, S. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2025.03.004 · Cited by 51

Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy

Ruppel, K. E., Fricke, S., Koehl, U., & Schmiedel, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.822298 · Cited by 53

CAR-T-Derived Extracellular Vesicles: A Promising Development of CAR-T Anti-Tumor Therapy

Pagotto, S., Simeone, P., Brocco, D., Catitti, G., Bellis, D. D., Vespa, S., Pietro, N. D., Marinelli, L., Stefano, A. D., Veschi, S., et al. (2023) · Cancers · doi:10.3390/cancers15041052 · Cited by 53

Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma

Watanabe, K., Gomez, A. M., Kuramitsu, S., Siurala, M., Da, T., Agarwal, S., Song, D., Scholler, J., Rotolo, A., Posey, A. D., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008327 · Cited by 54

Gamma delta (γδ) T cells in cancer immunotherapy; where it comes from, where it will go?

Deng, J., & Yin, H.-N. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174803 · Cited by 53

Adoptive T cell therapy: Boosting the immune system to fight cancer

León, E. C., Ranganathan, R., & Savoldo, B. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101437 · Cited by 48

In vivo generation of CAR T cells in the presence of human myeloid cells

Ho, N., Agarwal, S., Milani, M., Cantore, A., Buchholz, C. J., & Thalheimer, F. B. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.06.004 · Cited by 48

Mechanisms of resistance to CAR T cell therapies

Singh, N., Orlando, E. J., Xu, J., Xu, J., Binder, Z. A., Collins, M. A., O’Rourke, D. M., & Melenhorst, J. J. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.002 · Cited by 48

Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches

Gu, T., Zhu, M., Huang, H., & Hu, Y. (2022) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200256 · Cited by 45

IFN-γ and TNF-α aggravate endothelial damage caused by CD123-targeted CAR T cell

Sun, Y., Wang, S., Zhao, L., Zhang, B., & Chen, H. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s205678 · Cited by 48

Mechanisms of and approaches to overcoming resistance to immunotherapy

Schultz, L. M., & Gardner, R. A. (2019) · Hematology · doi:10.1182/hematology.2019000018 · Cited by 45

Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies

Dabiri, H., Kozani, P. S., Habibi‐Anbouhi, M., Godarzee, M. M., Haddadi, M. H., Basiri, M., Ziaei, V., Sadeghizadeh, M., & Saffar, E. H. (2023) · Biomarker Research · doi:10.1186/s40364-023-00509-1 · Cited by 45

Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia

Chiesa, R., Georgiadis, C., Rashed, H., Preece, R., Hardefeldt, P., Chu, J., Selvage, J., Mishra, A. K., Ahmed, B., Adams, S. P., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2505478 · Cited by 50

In vivo site-specific engineering to reprogram T cells

Nyberg, W. A., Bernard, P.-L., Ngo, W., Wang, C. H., Ark, J., Rothrock, A., Borgo, G. M., Kimmerly, G. R., Jung, J. H., Allain, V., et al. (2026) · Nature · doi:10.1038/s41586-026-10235-x · Cited by 55

Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation

Bertaina, A., & Roncarolo, M. G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01342 · Cited by 45

Advances in CAR‐Engineered Immune Cell Generation: Engineering Approaches and Sourcing Strategies

Chen, Z., Hu, Y., & Mei, H. (2023) · Advanced Science · doi:10.1002/advs.202303215 · Cited by 46

Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector

Coradin, T., Keating, A. L., Barnard, A. R., Whilding, L. M., Pombal, D., Hannoun, Z., Lewis, J., Devarajan, G., Iqball, S., Burton, E., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.07.006 · Cited by 44

Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies

Leick, M. B., Maus, M. V., & Frigault, M. J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.022 · Cited by 43

T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts

Nasiri, F., Kozani, P. S., & Rahbarizadeh, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1063838 · Cited by 42

CD8+ chimeric antigen receptor T cells manufactured in absence of CD4+ cells exhibit hypofunctional phenotype

Lee, S. Y., Lee, D. H., Sun, W., Cervantes-Contreras, F., Basom, R., Wu, F., Liu, S., Rai, R., Mirzaei, H. R., O’Steen, S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007803 · Cited by 42

Immunotherapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: Advances and Ongoing Challenges

Jasinski, S., Reyes, F. A. D. L., Yametti, G. C., Pierro, J., Raetz, E. A., & Carroll, W. L. (2020) · Pediatric Drugs · doi:10.1007/s40272-020-00413-3 · Cited by 42

Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B‐cell acute lymphoblastic leukemia

Lim, S. S., Grupp, S. A., & DiNofia, A. M. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29123 · Cited by 44

Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy

Abu‐Sbeih, H., Tang, T., Ali, F. S., Luo, W., Neelapu, S. S., Westin, J. R., Okhuysen, P. C., Foo, W. C., Curry, J. L., Richards, D. M., et al. (2019) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000596 · Cited by 41

Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance

Wellhausen, N., Baek, J. S., Gill, S. I., & June, C. H. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00723-5 · Cited by 45

Beta-Adrenergic Signaling in Tumor Immunology and Immunotherapy

Wang, W., & Cao, X. (2019) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2019031188 · Cited by 43

New directions in chimeric antigen receptor T cell [CAR‐T] therapy and related flow cytometry

Maryamchik, E., Gallagher, K., Preffer, F. I., Kadauke, S., & Maus, M. V. (2020) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21880 · Cited by 43

A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell–Mediated Antitumor Responses in Human B-cell Malignancies

de Weerdt, I., Lameris, R., Scheffer, G. L., Vree, J., de Boer, R., Stam, A. G. M., van de Ven, R., Levin, M., Pals, S. T., Roovers, R. C., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0138 · Cited by 43

Best practices for the development, analytical validation and clinical implementation of flow cytometric methods for chimeric antigen receptor T cell analyses

Sarikonda, G., Mathieu, M., Natalia, M., Pahuja, A., Xue, Q., Pierog, P., Trampont, P. C., Decman, V., Reynolds, S., Hanafi, L., et al. (2020) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21985 · Cited by 44

Chimeric Antigen Receptor T-Cells: The Future Is Now

McHayleh, W. M., Bedi, P. S., Sehgal, R., & Solh, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8020207 · Cited by 42

CAR T Cells: A Snapshot on the Growing Options to Design a CAR

Holzinger, A., & Abken, H. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000172 · Cited by 40

Genetic in vivo engineering of human T lymphocytes in mouse models

Weidner, T., Agarwal, S., Perian, S., Fusil, F., Braun, G., Hartmann, J., Verhoeyen, E., & Buchholz, C. J. (2021) · Nature Protocols · doi:10.1038/s41596-021-00510-8 · Cited by 40

Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products

Nezhad, M. S., Abdollahpour‐Alitappeh, M., Rezaei, B., Yazdanifar, M., & Seifalian, A. M. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03067-z · Cited by 42

Tumors evading CARs—the chase is on

Rafiq, S., & Brentjens, R. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0212-6 · Cited by 39

CAR T cells for T-cell leukemias: Insights from mathematical models

Pérez‐García, V. M., León‐Triana, O., Rosa, M., & Pérez‐Martínez, A. (2020) · Communications in Nonlinear Science and Numerical Simulation · doi:10.1016/j.cnsns.2020.105684 · Cited by 39

Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature

Zhao, A., Zhao, M., Qian, W., Liang, A., Li, P., & Liu, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1063986 · Cited by 38

Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia

Oh, B. L. Z., Vinanica, N., Wong, D., & Campana, D. (2024) · Haematologica · doi:10.3324/haematol.2023.283848 · Cited by 43

Resisting CAR T-cell Therapy: A Case Study

(2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2018-139 · Cited by 1

Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells

Cordes, N., Kolbe, C., Lock, D., Holzer, T., Althoff, D., Schaefer, D., Blaeschke, F., Kotter, B., Karitzky, S., Rössig, C., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.013 · Cited by 19

Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts

Quintarelli, C., Guercio, M., Manni, S., Boffa, I., Sinibaldi, M., Cecca, S. D., Caruso, S., Abbaszadeh, Z., Camera, A., Cembrola, B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001514 · Cited by 10

Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report

Schultz, L. M., Patel, S., Davis, K. L., Ramakrishna, S., Sahaf, B., Bhatia, N., Baggott, C., Erickson, C., Majzner, R. G., Oak, J. S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001073 · Cited by 7

CAR antigens beyond recognition

Harjes, U. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0082-7